Plain-English translation of NCT02994433 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research is testing as a potential treatment for treatment-resistant major depression—a severe form of depression that doesn't improve with standard medications and therapy. Researchers will use brain imaging to understand exactly how this medication works in the brain by comparing brain activity in both healthy people and those with treatment-resistant depression before and after inhaling the medication.
About 15–20% of people with depression don't benefit from standard treatments, leaving them without effective options. Early research suggests this medication may help, but doctors need to understand how it actually affects the brain so they can develop better treatments for people struggling with this severe form of depression.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic multiple times over several months. During the study, you'll receive up to six brain imaging scans (MRI) and participate in two separate inhalation sessions—one where you breathe the medication and one where you breathe a placebo (inactive) gas. The sessions will be separated by at least one month. Researchers will scan your brain before and after each inhalation to see how the treatment affects brain activity related to mood and emotion.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States